Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 7:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 738 matching trials from the live ClinicalTrials.gov search.
Conditions
Healthy, Obesity, Hypertension
Interventions
LY3971297, Placebo, LY3971297 IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • San Antonio, Texas
Conditions
Dilated Cardiomyopathy
Interventions
AZD0233, AZD0233 Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Conditions
Obesity, Overweight
Interventions
NNC0638-0355, Placebo (NNC0638-0355)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Conditions
Chronic Low-back Pain
Interventions
Spinal Manipulation Therapy (SMT), Naloxone, Placebo, Mindfulness Based Stress Reduction Therapy (MT)
Other · Drug · Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Conditions
Healthy Participants
Interventions
BMS-986308, Placebo (for BMS-986308), Furosemide
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lenexa, Kansas
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3463251 in Healthy Participants

NCT03764774
Conditions
Healthy
Interventions
LY3463251, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
62
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 54 more
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
ALN-PNP, Tirzepatide, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
Tucson, Arizona • Coronado, California • Pasadena, California + 7 more
Conditions
Duchenne Muscular Dystrophy
Interventions
Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Sevasemten Dose 4, Sevasemten Dose 5, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
4 Years to 9 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 11 more
Conditions
Asthma
Interventions
Mepolizumab 100mg, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Long Beach, California • Riverside, California • Denver, Colorado + 10 more
Conditions
Telangiectasia, Hereditary Hemorrhagic
Interventions
Pazopanib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Los Angeles, California • Augusta, Georgia • St Louis, Missouri + 2 more
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity

NCT06842186
Conditions
Overweight and Obesity
Interventions
WVE-007
Drug
Lead sponsor
Wave Life Sciences USA, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona • Baltimore, Maryland
Conditions
Major Depressive Disorder
Interventions
BMS-986511, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 15 more
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

NCT06401044
Conditions
Thyroid Eye Disease
Interventions
AMG 732, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
12
States / cities
Little Rock, Arkansas • Newport Beach, California • Jacksonville, Florida + 9 more
Conditions
Rheumatoid Arthritis (RA)
Interventions
LY4213663, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
9
States / cities
Anniston, Alabama • Phoenix, Arizona • Clearwater, Florida + 6 more
Conditions
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease, CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Interventions
GDC-6599, GDC-6599-matching placebo, Mannitol
Drug · Other · Diagnostic Test
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Northridge, California • Coral Gables, Florida + 5 more
Conditions
Fuchs' Corneal Endothelial Dystrophy (FCED)
Interventions
Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution, Part A Placebo, Part B Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Edgewood, Kentucky • Boston, Massachusetts
Conditions
Healthy
Interventions
ACT-246475, Clopidogrel, Prasugrel, Placebo, Ticagrelor
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newark, New Jersey
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3154885 in Healthy Participants

NCT04014361
Conditions
Healthy
Interventions
LY3154885 - Capsule, Placebo - Capsule, Itraconazole, LY3154885 - Tablet
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Cachexia
Interventions
GSK2881078, Placebo, Itraconazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, Hereditary Angioedema - Type 3, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema Type III, Hereditary Angioedema (HAE), Hereditary Angioedema Type I and II, HAE With Normal C1 Esterase Inhibitor
Interventions
deucrictibant
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 9 more
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232 PIB (SDD), GSK2838232 PIB (API), Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Dermatitis, Atopic
Interventions
Bermekimab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Indianapolis, Indiana • Chesterfield, Michigan • Tulsa, Oklahoma + 2 more
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Flint, Michigan